

# Chapter 17

## Mast Cells and Tumor Microenvironment

Theoharis C. Theoharides, Konstantinos-Dionysios Alysandratos,  
Asimena Angelidou, and Bodi Zhang

**Abstract** Increasing evidence indicates that a unique immune cell, the mast cell, accumulates in the stroma surrounding certain tumors, especially mammary and pancreatic adenocarcinoma, as well as melanoma. Many molecules secreted by mast cells could benefit the tumor in at least four ways: (1) angiogenin, heparin and vascular endothelial growth factor (VEGF), which induce neovascularization; (2) proteases that disrupt the surrounding matrix and facilitate metastases; (3) growth factors such as, epidermal growth factor (EGF), nerve growth factor (NGF), platelet derived growth factor (PDGF) and stem cell factor (SCF); (4) histamine, IL-10 and transforming growth factor- $\beta$  (TGF- $\beta$ ), which are immunosuppressant, along with activation of certain dendritic cells that induce immunologic anergy. These actions could only occur through the unique ability of mast cells to release certain mediators selectively without degranulation. Blocking such release of pro-tumor mediators may constitute a novel therapeutic approach.

### Abbreviations

BBB	blood-brain-barrier
CRH	corticotropin-releasing hormone
CT	tryptase and chymase mast cells
CTMC	connective tissue mast cells

---

T.C. Theoharides (✉)

Molecular Immunopharmacology and Drug Development Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA

and

Department of Biochemistry, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA

and

Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA

e-mail: theoharis.theoharides@tufts.edu


DMBA	7, 12-dimethylbenz( $\alpha$ )anthracene
EGF	epidermal growth factor
hCBMCs	human umbilical cord blood-derived cultured mast cells
HDC	histidine decarboxylase
HMC-1	human leukemic mast cells
IFN- $\alpha$	interferon- $\alpha$
IFN- $\gamma$	interferon- $\gamma$
MDSCs	myeloid-derived stem cells
MMC	mucosal mast cells
MMP-9	metalloproteinase-9
NGF	nerve growth factor
NMU	nitrosomethylurea
NO	nitric oxide
NSCLC	non-small cell lung carcinomas
NT	neurotensin
PAR-1 and -2	protease-activated receptors
PDAC	pancreatic ductal adenocarcinoma
PDGF	platelet-derived growth factor
RBL-1	rat basophil leukemia cells
SCF	stem cell factor
SCLC	small cell lung carcinomas
SP	substance P
T mast cells	tryptase mast cells
TAMs	tumor-associated macrophages
TGF- $\beta$	transforming growth factor- $\beta$
TNF	tumor necrosis factor
TRAIL	TNF-related apoptosis-related ligand
TSLP	thymic stromal lymphopietin
VEGF	vascular endothelial growth factor
VPF	vascular permeability factor

## Introduction

Despite substantial resources invested in basic cancer research, mortality rates for the most frequent forms of cancer have not decreased significantly. Metastasis facilitated by stromal proteolytic enzymes (Almholt and Johnsen 2003) and chemokines (Murphy 2001) remains the chief cause of morbidity and mortality. The stroma surrounding the tumor is increasingly acquiring importance for its growth and dissemination, with infiltrating inflammatory cells actually contributing to cancer proliferation (Mantovani et al. 2002). For instance, tumor-associated macrophages (TAMs) and tumor-associated fibroblasts can be beneficial to tumor angiogenesis and growth (Silzle et al. 2003; Yu and Rak 2003) through secretion of vascular endothelial growth factor (VEGF) (Barbera-Guillem et al. 2002) and platelet-derived growth factor (PDGF) (Kataki et al. 2002). In one model of

subcutaneous melanoma, both angiogenesis and growth rate correlated with tumor infiltration by macrophages that expressed angiotensin II type 1 receptor and VEGF (Egami et al. 2003). TAMs were also significantly correlated with squamous cell carcinoma invasion (Li et al. 2002).

Mast cells are important in allergic and late phase reactions, but also in inflammation and T-cell mediated immune responses (Mekori and Metcalfe 2000; Redegeld and Nijkamp 2003; Pedotti et al. 2003). Yet, mast cells appear to be recruited by tumors and accumulate in the stroma (Theoharides 1988) (Fig. 17.1). Mast cells could be helpful to the tumor, but only if secretion of beneficial molecules could occur *selectively without degranulation* (Theoharides et al. 2007). In fact, the tumor stroma microenvironment could alter the phenotypic behavior of mast cells. For instance, acidity created by rapid cancer cell proliferation inhibits mast cell degranulation, but enhances IL-4 production (Frossi et al. 2003). Nitric oxide (NO) generated by new vessel growth inhibits mast cell degranulation (Coleman 2002), as do oxidized polyamines secreted by the tumor (Vliagoftis et al. 1992). Mast cells can promote tumor development by: (a) disturbing the normal stroma-epithelium



**Fig. 17.1** Schematic representation of the possible role of increased number of mast cells in the stroma of certain tumors. Mast cells could be recruited by tumor-derived chemoattractants such as adrenomedullin, MCP-1, RANTES and SCF, to selectively secrete molecules beneficial to the tumor; these could include growth factors, histamine which is mitogenic ( $H_1$ ) and immunosuppressant ( $H_2$ ), neovascularization agents such as heparin, VEGF and IL-8, as well as proteases that could permit new blood vessel formation and metastases

communication as was shown for matrix degradation at sites of tumor invasion in rat mammary adenocarcinoma, (b) facilitating tumor angiogenesis, (c) releasing growth factors (Conti et al. 2007), and (d) inducing a state of immunosuppression. The tumor enhancing effect of mast cells has been shown repeatedly with the use of W/W<sup>v</sup> mast cell deficient mice, which developed fewer lung metastases to subcutaneous B16-BL6 tumors (Starkey et al. 1988), and in which mice premetastatic angiogenesis of squamous epithelial carcinogenesis was blocked (Coussens et al. 1999). The development of 1, 2-dimethylhydrazine-induced intestinal tumors was slowed by 60% in W/W<sup>v</sup> mice (Wedemeyer and Galli 2005). There was also reduced microvessel formation and tumor size in W/W<sup>v</sup> mice injected with MB49 murine bladder carcinoma (Dethelsen et al. 1994).

## Mast Cell Biology

Mast cells derive from a specific bone marrow progenitor cell, they migrate into tissues where they mature depending upon microenvironmental conditions, and they participate in allergic reactions, as well as innate and acquired immunity (Mekori and Metcalfe 2000; Galli et al. 2005a, b). Mast cells are located perivascularly close to neurons and could have a critical role in neuroinflammatory diseases (Theoharides and Cochrane 2004), as well as in stress-induced brain metastases (Theoharides et al. 2008). Mast cells vary considerably in their cytokine and proteolytic enzyme content: connective tissue mast cells (CTMC) contain tryptase and chymase (CT mast cells), while mucosal mast cells (MMC) contain only tryptase (T mast cells). However, the phenotypic expression of mast cells is not fixed, since MMC can develop into CTMC given the appropriate microenvironmental conditions (Galli et al. 2005a). Moreover, addition of IL-5 to human umbilical cord blood-derived cultured mast cells (hCBMCs) augmented IgE-induced production of distinct cytokines, such as tumor necrosis factor (TNF) and MIP-1 $\alpha$ , but without histamine (Ochi et al. 2000).

In addition to IgE and antigen, the main trigger in allergic reactions, anaphylatoxins (C3a, C5a), cytokines (IL-1, IL-33), hormones (CRH) and neuropeptides can stimulate mast cell activation; the latter include endorphins, substance P (SP), neurotensin (NT), and nerve growth factor (NGF) leading to secretion of numerous biologically active mediators, but through different pathways (Theoharides and Kalogeromitros 2006). In addition, thymic stromal lymphopoietin (TSLP) released from epithelial cells in response to infection, trauma, and inflammation activates mast cells in the absence of IgE, but in the presence of IL-1, to release IL-5 and IL-13 (Allakhverdi et al. 2007; Al-Shami et al. 2005).

Mast cells can secrete either the content of individual granules (Theoharides and Douglas 1978) or distinct mediators selectively (Theoharides et al. 1982), possibly through regulation by specific phosphoproteins (Sieghart et al. 1978; Theoharides et al. 1980). Vascular permeability/vascular endothelial cell growth factor (VPF/VEGF) can be secreted from bone marrow-derived mouse mast cells

(Boesiger et al. 1998). In view of the fact that acute stress increased tumor size and decreased survival (Sklar and Anisman 1979; Antoni et al. 2006), we investigated if corticotropin-releasing hormone (CRH), secreted under stress, could induce VEGF release from hCBMCs. We reported that CRH induced selective VEGF release without histamine (Cao et al. 2005). We further showed that IL-1 could induce selective secretion of IL-6 from hCBMCs without degranulation through a unique vesicular shuttle (Kandere-Grzybowska et al. 2003). IL-1 can further stimulate secretion of VEGF (Salven et al. 2002), thus promoting angiogenesis (Salven et al. 2002) and lung carcinoma growth (Saijo et al. 2002). Stem cell factor (SCF) can also induce selective release of IL-6 without histamine and without degranulation (Gagari et al. 1997). This process has been termed “differential release”, “intragranular activation” or “piecemeal degranulation” (Letourneau et al. 1996). Moreover, in certain diseases such as scleroderma and interstitial cystitis (Theoharides et al. 1995), mast cells could be almost totally depleted of their granule content, without classic degranulation, rendering them undetectable by light microscopy (“phantom mast cells”) (Claman et al. 1986).

## Mast Cells Could Be Beneficial to the Tumor

Mast cells could accumulate at sites of tumor growth in response to numerous chemoattractants (Table 17.1) such as RANTES or MCP-1 (Conti et al. 1997), and are associated with poor prognosis (Molin et al. 2002). In addition, SCF at low doses mediates chemotaxis of mast cells, while a higher dose is necessary for release of mediators (Huang et al. 2008), such as metalloproteinase-9 (MMP-9) (Huang et al. 2008). Adrenomedullin can stimulate histamine release from rat peritoneal mast cells (Yoshida et al. 2001), but can also be released from human cultured A549 lung carcinoma cells and stimulate human leukemic mast cells (HMC-1) (Zudaire et al. 2006). Moreover, adrenomedullin is also produced by HMC-1 cells, it augments growth of lung cancer cells (Zudaire et al. 2006), and adrenomedullin-producing mast cells were shown to infiltrate human lung cancers (Zudaire et al. 2006).

Mast cells have been consistently implicated in tumor angiogenesis (Crivellato et al. 2008), along with other myeloid cells (Murdoch et al. 2008). Mast cell-deficient W/W<sup>v</sup> mice exhibited decreased rate of tumor angiogenesis (Starkey et al. 1988). Mast cells could facilitate tumor angiogenesis through heparin-like molecules that would also permit metastases through their anti-clotting effects (Fig. 17.1). Mast cells

**Table 17.1** Tumor-derived mast cell chemoattractants/triggers

- 
- Adrenomedullin
  - MCP-1
  - RANTES
  - SCF
-

also generate and secrete IL-8 which has been shown to be an angiogenesis factor, as well as a tumor cell chemotactic factor and tumor mitogen (Waugh and Wilson 2008). Mast cells secrete a number of growth factors, such as EGF, PDGF, NGF, and SCF (Galli et al. 2005b). Moreover, VPF/VEGF is secreted from mouse bone marrow-derived and human cultured mast cells (Boesiger et al. 1998), as well as from HMC-1 cells (Grutzkau et al. 1998) (Table 17.2).

Mast cells are rich in metalloproteinases, such as MMP-9, that can facilitate tumor invasiveness (Almholt and Johnsen 2003). Such enzymes can disturb the normal stroma-epithelium communication, as was shown for matrix degradation at sites of tumor invasion in rat mammary adenocarcinoma (Dabbous et al. 1986). Mast cells and stress could also disrupt the blood-brain-barrier (BBB) and promote brain metastases (Theoharides et al. 2008). Acute stress can activate mast cells and increase BBB permeability that is mast cell dependent (Esposito et al. 2002a). These findings are important in view of the fact that acute stress increases metastases in breast and other tumors (Sklar and Anisman 1979; Antoni et al. 2006), and over 30% of breast cancer patients develop brain metastases with poor associated prognosis (Schouten et al. 2002). In fact, a number of cancers express CRH receptors (Reubi et al. 2003), prompting the suggestion that CRH may affect tumor cell behavior. For instance, a human breast cancer line MCF7 expresses CRH mRNA and secretes immunoreactive CRH (Graziani et al. 2006b), prompting the possibility of autocrine or paracrine effects.

Another aspect of tumor microenvironment is immunosuppression. Histamine induces tumor cell proliferation through H1 receptors, while suppressing the immune system through H2 and possibly H4 receptors (Tiligada et al. 2009; Gutzmer et al. 2005). It was also shown that the histamine content of human breast

**Table 17.2** Mast cell mediators relevant to tumor microenvironment

Mediators	Main pathophysiologic effects
Histamine	Vasodilation, mitogenesis, immunosuppression
Enzymes	
Chymase	Tissue damage
Metalloproteinases	Tissue disruption, metastases
Trypsase	Tissue damage, metastases
Growth factors	Tumor growth
EGF, GM-CSF, NGF, PDGF, SCF	
Angiogenic factors	Angiogenesis, neovascularization
Angiogenin	
Heparin	
VEGF	
Cytokines	
IL-8	Chemoattractant, tumor mitogen

*EGF* epidermal growth factor, *GM-CSF* granulocyte monocyte-colony stimulating factor, *NGF* nerve growth factor, *PDGF* platelet-derived growth factor, *SCF* stem cell factor, *VEGF* vascular endothelial cell growth factor

cancer tissue was much higher than adjacent normal tissue and sufficient to act as a local immunosuppressant (Reynolds et al. 1998). The H2 receptor antagonist, famotidine, given preoperatively enhanced tumor infiltrating lymphocytes and increased metastatic lymph node reactive changes in breast cancer in humans (Parshad et al. 2002). Mast cells can promote immunosuppression by also secreting the immunosuppressants transforming growth factor- $\beta$  (TGF- $\beta$ ) and IL-10 (Conti et al. 2003). SCF-mediated mast cell infiltration of tumors further enhances immunosuppression (Huang et al. 2008). Mast cells may further contribute to tumor energy by promoting the development/recruitment of “tolerogenic host antigen-presenting cells” (Wasiuk et al. 2009) and Treg cells (Wasiuk et al. 2009). Mast cells may also influence migration and function of dendritic cells through distinct prostaglandins (PGE<sub>2</sub> and PGD<sub>2</sub>) (Wasiuk et al. 2009). In addition, mast cells could indirectly down-regulate anti-tumor immunity by influencing the functions of immune suppressive myeloid-derived stem cells (MDSCs). MDSCs also secrete VEGF (Marx 2008), but this action requires MMP-9 (Yang et al. 2004), which is produced by mast cells. Mast cell-derived IL-1b induces MDSCs in mice with transplanted mammary carcinoma or fibrosarcoma (Bunt et al. 2006).

## Breast Cancer

Disruption of the normal flow of information between stroma and parenchyma could permit neoplastic progression (Barcellos-Hoff 1998). Stromal matrix metalloproteinases, rather than the target cell, were shown to promote mammary tumorigenesis (Sternlicht et al. 1999), while irradiated mammary gland stroma promoted carcinogenesis of unirradiated epithelial cells (Barcellos-Hoff and Ravani 2000). Mammary carcinogenesis in Wistar/Furth rats occurs when *only* the stroma of the mammary gland (fat pad) is exposed to the carcinogen nitrosomethylurea (NMU) (Maffini et al. 2004). The earliest effects of carcinogen administration in mammary gland carcinogenesis are manifested in the stroma with infiltration of inflammatory cells including mast cells (Maffini et al. 2004). The number of mast cells was significantly increased in malignant as compared to benign, lesions in human breast biopsies (Kashiwase et al. 2004). Moreover, the number of mast cells was greater in scirrhous than papillotubular carcinoma (Kashiwase et al. 2004). The histamine content of human breast cancer tissue, an index of mast cell presence, was much higher than adjacent normal tissue (Reynolds et al. 1998). Recent papers also confirmed high number of mast cells in human mammary adenocarcinoma (Rajput et al. 2007; Ribatti et al. 2007). Some of these papers suggested that the presence of mast cells may indicate a favorable prognosis (Rajput et al. 2007; Dabiri et al. 2004); however, in these instances mast cells were “identified” by staining for c-kit (Rajput et al. 2007; Dabiri et al. 2004), which is not specific, as cancer cells also express c-kit (Charpin et al. 2009). Moreover, reduction of c-kit expression was associated with malignant transformation of breast epithelium in human breast cancer (Polat 2007), and in carcinogen-induced rat mammary carcinoma (Maffini

et al. 2008). Consequently, tumor c-kit expression and not the presence of c-kit positive mast cells, appears to be associated with favorable outcomes.

An increased number of mast cells was reported in cis-hydroxyproline-induced mammary tumors in Buffalo rats (Strum et al. 1981). Similar findings were obtained in 7, 12-dimethylbenz( $\alpha$ )anthracene (DMBA)-induced mammary adenocarcinoma in which mast cells accumulated, but appeared to be intact and resistant to the mast cell degranulator compound 48/80 (Andersson et al. 1976). The mast cell inhibitor disodium cromoglycate increased blood clotting and hypoxia in invasive murine breast cancer (Samoszuk and Corwin 2003).


The location of mast cells in relation to tumor cells may also be important. Lymph nodes may behave differently (Munn and Mellor 2006) upon cancer cell entrapment. Tryptase-positive mast cells correlated with angiogenesis and presence of micrometastases in sentinel lymph nodes from 80 patients with breast cancer (Ribatti et al. 2007). In contrast, intermammary lymph node enlargement with mast cell infiltration was considered to be a positive prognostic sign (Quan et al. 2002).

## Melanoma and Basal Cell Carcinoma

Mast cells accumulate especially around invasive melanoma (Reed et al. 1996; Dvorak et al. 1980), and their numbers correlate with increased neovascularization, mast cell overexpression of VEGF, tumor aggressiveness, and poor prognosis (Ch'ng et al. 2006). Tumor vascularity and tryptase-positive mast cells correlated with poor melanoma prognosis (Ribatti et al. 2003). Moreover, SCF splice variants were detected in melanoma (Welker et al. 2000), and could present new forms of mast cell growth factors related to melanoma growth. Mast cells have also been repeatedly noted to accumulate around basal cell carcinoma lesions and are thought to contribute to cancer growth by inducing immunosuppression (Grimbaldeston et al. 2000). Increased dermal mast cell numbers are associated with higher risk of developing basal cell carcinoma in humans possibly through UVB-induced immunosuppression (Grimbaldeston et al. 2002). Mast cells can also mediate TNF- $\alpha$  dependent dendritic cell migration and consequently increase skin tumor antigen presentation, but in a manner that does not elicit an immune response (Munn and Mellor 2006; Hart et al. 2002).

## Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the 4th cause of cancer-related deaths in the USA, with a prognosis of less than 6.0 months and 5-year survival of less than 5% (Welsch et al. 2007; Hezel et al. 2006). PDAC escapes early detection and resists treatment (Tuveson and Hingorani 2005). Even though PDAC had been



**Fig. 17.2** Light photomicrograph of ductal pancreatic adenocarcinoma with a number of infiltrating intact mast cells (*solid arrows*) stained with acidified toluidine blue, magnification = 20×

thought not to be particularly vascular, it was shown to secrete VEGF (Luo et al. 2001). Adrenomedullin, discussed earlier as a mast cell trigger, is expressed by pancreatic cancer cells and increases their growth and survival (Nakamura et al. 2006; Keleg et al. 2007). Increased numbers of mast cells have also been noted in pancreatic cancer (Esposito et al. 2002b, 2004). Moreover, a recent paper reported that mast cells were an absolute requirement for angiogenesis and cancer development in *Myc*-activated mouse pancreatic tumors (Soucek et al. 2007). Mast cells are actually localized among ductal adenocarcinoma cells, and they appear morphologically intact (Fig. 17.2), suggesting that pro-tumor molecules may be released without degranulation.

## Lung Cancer

The relevance of lung mast cells to lung cancer is intriguing, given that mast cells are well known to be increased in asthma and other inflammatory lung diseases (Krishnaswamy et al. 2007). In fact, lung mast cells are also increased in the epithelium of smokers (Lamb and Lumsden 1982), especially in the small airways (Battaglia et al. 2007). Gene profiling of disaggregated human lung mast cells from patients with interstitial diseases showed increased expression of matrix metalloproteinases (Edwards et al. 2005). The number of mast cells was increased in bronchoalveolar lavage of patients with bronchial carcinoma (Walls et al. 2007). Also, increased mast cell density using tryptase and surface CD34 immunocytochemistry was significantly correlated with tumor progression, angiogenesis and poor prognosis in human adenocarcinomas (Takanami et al. 2000). High counts of

chymase-positive mast cells also correlated with worse prognosis in bronchoalveolar carcinoma (Nagata et al. 2003) and in lung adenocarcinoma (Ibaraki et al. 2005). This direct correlation between increased numbers of mast cells and lung cancer was apparently independent of tumor angiogenesis, as measured by the presence of endothelial cells stained with anti-human factor VIII antibody (Tomita et al. 2000). Nevertheless, increased mast cell density correlated with increased VEGF expression and poor prognosis in 33/53 cases of non-small cell lung carcinomas (NSCLC) (Imada et al. 2000). Histidine decarboxylase (HDC) immunoreactivity, an index of mast cell presence/activation, could distinguish 18/23 cases of small cell lung carcinomas (SCLC), but only 6/12 cases of NSCLC (Matsuki et al. 2003), suggesting that higher number of mast cells were infiltrating the SCLC, known to be more aggressive.

## Mast Cells Could be Detrimental to the Tumor

Even though mast cells could be detrimental to tumor growth, they apparently cannot secrete such mediators as they may be inhibited from degranulation by tumor-derived blockers, such as oxidized polyamines (Vliagoftis et al. 1992), or chondroitin sulfate, which inhibits mast cell activation (Theoharides et al. 2000). It would be fascinating if one could inhibit mast cells from secreting pro-tumor mediators, but promote secretion of anti-tumor molecules. For instance, tryptase stimulates protease-activated receptors (PAR-1 and -2), also activated by thrombin and trypsin respectively, and induces widespread inflammation (D'Andrea et al. 2001). IL-4 binds to IL-4 receptors expressed by human breast carcinoma cells, and leads to apoptosis (Gooch et al. 1998). TNF- $\alpha$  could also induce tumor cell death (Gordon and Galli 1990). Histamine inhibited human primary melanoma cell proliferation presumably by acting through H1 receptors, an action enhanced by IL-6 (Lazar-Molnar et al. 2002). Heparan sulfate proteoglycans could block binding of heparin to the cell surface and prevent neovascularization (Fannon et al. 2003). For instance protamine, which binds to heparin and neutralizes its anticoagulant properties, induced selective thrombosis of blood vessels within mammary adenocarcinoma (Su et al. 2001). On the other hand, cancer cell-associated chondroitin sulfate accumulates in mammary gland tumors and in metastatic lesions (Hinrichs et al. 1999); in fact, tumor cells metastasize through binding of their surface chondroitin sulfate to the interstitial matrix (Kokenyesi 2001).

Interferon- $\alpha$  (IFN- $\alpha$ ) or mast cell-derived interferon- $\gamma$  (IFN- $\gamma$ ) may enhance TNF-related apoptosis-related ligand (TRAIL) gene expression and translation, leading to apoptosis of tumor cells in an autocrine and paracrine manner (Abadie et al. 2004; Wang et al. 2004). Moreover, treatment of melanoma patients with IFN- $\alpha$  increased TRAIL levels in serum (Tecchio et al. 2004). Receptor binding of TRAIL, in turn, activates an number of down stream events leading to regulation of the inflammatory response (Collison et al. 2009). In addition to its cytotoxic role,

TRAIL can inhibit angiogenesis indirectly by facilitating apoptosis of endothelial cells (Li et al. 2003).

Certain studies indicate that CRH may inhibit growth of endometrial (Graziani et al. 2002) and breast cancer cells (Graziani et al. 2006b) in culture. Other studies suggest that endometrial cancer not expressing CRHR-1 may be associated with a more aggressive phenotype in humans (Graziani et al. 2006a). Mast cells (Kempuraj et al. 2004) and other inflammatory cells (Karalis et al. 1997) can synthesize and release CRH. It would, therefore, be interesting if mast cells could release CRH, but at the same time be prevented from CRH inducing VEGF release in an autocrine fashion.

## Conclusion

Mounting evidence indicates that mast cells accumulate in tumor stroma and can promote tumor growth and metastases. Mast cells may, therefore, serve as a new target for the adjuvant treatment of tumors (Groot et al. 2009), such as mammary adenocarcinoma or pancreatic cancer (Theoharides 2008), through the selective inhibition of tumor-promoting molecules. A possible therapeutic approach could involve the use of select flavonoids. Flavonoids are naturally occurring polyphenolic compounds present in green plants and seeds with anti-oxidant, anti-inflammatory and cancer-inhibiting properties (Middleton et al. 2000). A multiethnic epidemiological study identified an inverse relationship between flavonoid intake and pancreatic cancer (Nothlings et al. 2007). An inverse relationship has also been reported between intake of flavonoids, such as quercetin, and risk of lung cancer in general (Le Marchand et al. 2000), as well as in male smokers in particular (Hirvonen et al. 2001). The flavonoids quercetin, luteolin and epigallocatechin also decrease proliferation of pancreatic carcinoma cells in culture (Lee et al. 2002; Shankar et al. 2008; Takada et al. 2002), but the mechanism of this action is not known. We showed that these flavonoids inhibit proliferation and secretion from rat basophil leukemia (RBL-1) cells (Alexandrakis et al. 1999) and HMC-1 cells (Alexandrakis et al. 2003), as well as pro-inflammatory cytokine release from normal hCBMCs (Kempuraj et al. 2005). In fact, recent reviews have re-emphasized the potential use of select flavonoids, such as epigallocatechin, quercetin and curcumin in cancer treatment (Saif et al. 2009; Sogno et al. 2009; Jagtap et al. 2009).

Future studies should investigate any unique ability of select flavonoids with anti-cancer properties to also inhibit secretion of pro-cancer molecules, while permitting secretion of anti-cancer mediators from mast cells.

**Acknowledgments** Work discussed was supported in part by a "Concept Award" No. BC024430 from the United States Department of Defense to (TCT), and funds from Theta Biomedical Consulting and Development Co., Inc. (Brookline, MA). The possible therapeutic role of inhibiting mast cell-derived molecules beneficial to tumor growth is covered by patent application US 10/811,838 submitted by TCT and assigned to Theta, Inc.

Many thanks are due to Dr. Eva Karamitropoulou (Attikon General Hospital, Athens Medical School, Athens, Greece) for the pancreatic cancer photo, and to Ms. Jessica Christian for her word processing skills.

## References

- Abadie A, Besancon F, Wietzerbin J (2004) Type I interferon and TNF $\alpha$  cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells. *Oncogene* 23:4911–4920
- Alexandrakis M, Singh L, Boucher W, Letourneau R, Theofilopoulos P et al (1999) Differential effect of flavonoids on inhibition of secretion and accumulation of secretory granules in rat basophilic leukemia cells. *Int J Immunopharmacol* 21:379–390
- Alexandrakis MG, Letourneau R, Kempuraj D, Kandere K, Huang M et al (2003) Flavones inhibit proliferation and increase mediator content in human leukemic mast cells (HMC-1). *Eur J Haematol* 71:448–454
- Allakhverdi Z, Comeau MR, Jessup HK, yoon BP, Breuer A et al (2007) Thymic stromal lymphopoietin is released by human epithelial cell in response to microbes, trauma, or inflammation and potently activates mast cells. *J Exp Med* 19:253–258
- Almholt K, Johnsen M (2003) Stromal cell involvement in cancer. *Cancer Res* 162:31–42
- Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ (2005) A role for TSLP in the development of inflammation in an asthma model. *J Exp Med* 202:829–839
- Andersson A-C, Henningson S, Lundell L, Rosengren E, Sundler F (1976) Diamines and polyamines in DMBA-induced breast carcinoma containing mast cells resistant to compound 48/80. *Agents Actions* 6/5:577–583
- Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE et al (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. *Nat Rev Cancer* 6:240–248
- Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW (2002) Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. *Cancer Res* 62:7042–7049
- Barcellos-Hoff MH (1998) The potential influence of radiation-induced microenvironments in neoplastic progression. *J Mammary Gland Biol Neoplasia* 3:165–175
- Barcellos-Hoff MH, Ravani SA (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. *Cancer Res* 60:1254–1260
- Battaglia S, Mauad T, van Schadewijk AM, Vignola AM, Rabe KF et al (2007) Differential distribution of inflammatory cells in large and small airways in smokers. *J Clin Pathol* 60: 907–911
- Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF et al (1998) Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fc $\epsilon$  receptor I expression. *J Exp Med* 188:1135–1145
- Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. *J Immunol* 176:284–290
- Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K et al (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 174:7665–7675
- Charpin C, Giusiano S, Charfi S, Secq V, Carpentier S et al (2009) Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome. *Br J Cancer* 101:48–54

- Ch'ng S, Waallis RA, Yuan L, Davis PF, Tan ST (2006) Mast cells and cutaneous malignancies. *Mod Pathol* 19:149–159
- Claman HN, Choi KL, Sujansky W, Vatter AE (1986) Mast cell “disappearance” in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of “phantom mast cells”. *J Immunol* 137:2009–2013
- Coleman JW (2002) Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. *Clin Exp Immunol* 129:4–10
- Collison A, Foster PS, Mattes J (2009) The emerging role of TRAIL as key regulator of inflammatory responses. *Clin Exp Pharmacol Physiol* 36:1049–1053
- Conti P, Pang X, Boucher W, Letourneau R, Reale M et al (1997) Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. *Blood* 89: 4120–4127
- Conti P, Kempuraj D, Kandere K, Gioacchino MD, Barbacane RC et al (2003) IL-10, an inflammatory/inhibitory cytokine, but not always. *Immunol Lett* 86:123–129
- Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J et al (2007) Role of mast cells in tumor growth. *Ann Clin Lab Sci* 37:315–322
- Coussens LM, Raymond WW, Nergers G, Laig-Webster M, Behrendtsen O et al (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. *Genes Dev* 13:1382–1397
- Crivellato E, Nico B, Ribatti D (2008) Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. *Cancer Lett* 269:1–6
- D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P (2001) Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. *Am J Pathol* 158:2031–2041
- Dabbous MK, Walker R, Haney L, Carter LM, Nicolson GL et al (1986) Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarcinoma. *Br J Cancer* 54:459–465
- Dabiri S, Huntsman D, Makretsov N, Cheang M, Gilks B et al (2004) The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. *Mod Pathol* 17:690–695
- Dethlefsen SM, Matsumura N, Zetter BR (1994) Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. *Invasion Metastasis* 14:395–408
- Dvorak AM, Mihm MCJ, Osage JE, Dvorak HF (1980) Melanoma. An ultrastructural study of the host inflammatory and vascular responses. *J Invest Dermatol* 75:388–393
- Edwards ST, Cruz AC, Donnelly S, Dazin PF, Schulman ES et al (2005) c-Kit immunophenotyping and metalloproteinase expression profiles of mast cells in intestinal lung diseases. *J Pathol* 206:279–290
- Egami K, Murohara T, Shimada T, Sasaki K, Shintani S et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. *J Clin Invest* 112:67–75
- Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S et al (2002a) Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. *J Pharmacol Exp Ther* 303:1061–1066
- Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P et al (2002b) The stem cell factor-c-kit system and mast cells in human pancreatic cancer. *Lab Invest* 82:1481–1492
- Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U et al (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. *J Clin Pathol* 57:630–636
- Fannon M, Forsten-Williams K, Dowd CJ, Freedman DA, Folkman J et al (2003) Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. *FASEB J* 17:902–904

- Frossi B, De Carli M, Daniel KC, Rivera J, Pucillo C (2003) Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway. *Eur J Immunol* 33:2168–2177
- Gagari E, Tsai M, Lantz CS, Fox LG, Galli SJ (1997) Differential release of mast cell interleukin-6 via c-kit. *Blood* 89:2654–2663
- Galli SJ, Kalesnikoff J, Grimbaldston MA, Piliponsky AM, Williams CM et al (2005a) Mast cells as “tunable” effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 23:749–786
- Galli SJ, Nakae S, Tsai M (2005b) Mast cells in the development of adaptive immune responses. *Nat Immunol* 6:135–142
- Gooch JL, Lee AV, Yee D (1998) Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. *Cancer Res* 58:4199–4205
- Gordon JR, Galli SJ (1990) Mast cells as a source of both preformed and immunologically inducible TNF- $\alpha$ /cachectin. *Nature* 346:274–276
- Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G et al (2002) CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. *Endocrinology* 143:807–813
- Graziani G, Ferrandina G, Pozzoli G, Vergati M, Muzi A et al (2006a) Corticotropin-releasing hormone receptor-1 in human endometrial cancer. *Oncol Rep* 15:375–379
- Graziani G, Tentori L, Muzi A, Vergati M, Tringali G et al (2006b) Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRHR1 receptor subtype. *Mol Cell Endocrinol* 264:44–49
- Grimbaldston MA, Skov L, Baadsgaard O, Skov BG, Marshman G et al (2000) Communications: high dermal mast cell prevalence is a predisposing factor for basal cell carcinoma in humans. *J Invest Dermatol* 115:317–320
- Grimbaldston MA, Skov L, Finlay-Jones JJ, Hart PH (2002) Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans. *Methods* 28:90–96
- Groot KT, Abudukelimu A, Redegeld FA (2009) Mast cells as target in cancer therapy. *Curr Pharm Des* 15:1868–1878
- Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H et al (1998) Synthesis, storage and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF<sub>206</sub>. *Mol Biol Cell* 9:875–884
- Gutzmer R, Diestel C, Mommert S, Kother B, Stark H et al (2005) Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. *J Immunol* 174:5224–5232
- Hart PH, Townley SL, Grimbaldston MA, Khalil Z, Finlay-Jones JJ (2002) Mast cells, neuropeptides, histamine, and prostaglandins in UV-induced systemic immunosuppression. *Methods* 28:79–89
- Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* 20:1218–1249
- Hinrichs U, Rutteman A, Nederbragt H (1999) Stromal accumulation of chondroitin sulphate in mammary tumours of dogs. *Br J Cancer* 80:1359–1365
- Hirvonen T, Tornwali ME, Pietinen P, Albanes D, Vitamo J (2001) Flavonol and flavone intake and the risk of cancer in male smokers (Finland). *Cancer Causes Control* 12:789–796
- Huang B, Lei Z, Zhang GM, Li D, Song C et al (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. *Blood* 112:1269–1279
- Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H et al (2005) The relationship of tryptase and chymase positive mast cells to angiogenesis in stage I non-small cell lung cancer. *Eur J Cardiothorac Surg* 28:621
- Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. *Eur Respir J* 15:1087–1093

- Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J et al (2009) Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. *Curr Med Chem* 16:1451–1462
- Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S et al (2003) IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol* 171:4830–4836
- Karalis K, Louis JM, Bae D, Hilderbrand H, Majzoub JA (1997) CRH and the immune system. *J Neuroimmunol* 72:131–136
- Kashiwase Y, Morioka J, Inamura H, Yoshizawa Y, Usui R et al (2004) Quantitative analysis of mast cells in benign and malignant breast lesions. Immunohistochemical study on formalin-fixed, paraffin-embedded tissues. *Int Arch Allergy Immunol* 134:199–205
- Kataki A, Scheid P, Piet M, Marie B, Martinet N et al (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. *J Lab Clin Med* 140:320–328
- Keleg S, Kayed H, Jiang X, Penzel R, Giese T et al (2007) Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. *Int J Cancer* 121:21–32
- Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K et al (2004) Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology* 145:43–48
- Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J et al (2005) Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. *Br J Pharmacol* 145:934–944
- Kokenyesi R (2001) Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. *J Cell Biochem* 83:259–270
- Krishnaswamy G, Ajitawi O, Chi DS (2007) The human mast cells. *Methods Mol Biol* 315:13–34
- Lamb D, Lumsden A (1982) Intra-epithelial mast cells in human airway epithelium: evidence for smoking-induced changes in their frequency. *Thorax* 37:334–342
- Lazar-Molnar E, Hegyesi H, Pallinger E, Kovacs P, Toth S et al (2002) Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. *Eur J Clin Invest* 32:743–749
- Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN (2000) Intake of flavonoids and lung cancer. *J Natl Cancer Inst* 92:154–160
- Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC et al (2002) Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. *Anticancer Res* 22:1615–1627
- Letourneau R, Pang X, Sant GR, Theoharides TC (1996) Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *Br J Urol* 77:41–54
- Li C, Shintani S, Terakado N, Nakashiro K, Hamakawa H (2002) Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma. *Oncol Rep* 9:1219–1223
- Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS (2003) TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. *J Immunol* 171:1526–1533
- Luo J, Guo P, Matsuda K, Truong N, Lee A et al (2001) Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. *Int J Cancer* 92:361–369
- Maffini MV, Soto AM, Calabro JM, Ucol AA, Sonnenschein C (2004) The stroma as a crucial target in rat mammary gland carcinogenesis. *J Cell Sci* 117:1495–1502
- Maffini MV, Soto AM, Sonnenschein C, Papadopoulos N, Theoharides TC (2008) Lack of c-kit receptor promotes mammary tumors in N-nitrosomethylurea-treated Ws/Ws rats. *Cancer Cell Int* 8:5
- Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol* 23:549–555

- Marx J (2008) Cancer immunology. Cancer's bulwark against immune attack: MDS cells. *Science* 319:154–156
- Matsuki Y, Tanimoto A, Hamada T, Sasaguri Y (2003) Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. *Mod Pathol* 16:72–78
- Mekori YA, Metcalfe DD (2000) Mast cells in innate immunity. *Immunol Rev* 173:131–140
- Middleton E Jr, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. *Pharmacol Rev* 52:673–751
- Molin D, Edstrom A, Glimelius I, Glimelius B, Nilsson G et al (2002) Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. *Br J Haematol* 119:122–124
- Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. *Immunol Rev* 213:146–158
- Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis. *Nat Rev Cancer* 8:618–631
- Murphy PM (2001) Chemokines and the molecular basis of cancer metastasis. *N Engl J Med* 345:833–835
- Nagata M, Shijubo N, Waalls AF, Ichimiya s, Abe S et al (2003) Chymase positive mast cells in small sized adenocarcinoma of the lung. *Virchows Arch* 443:565–573
- Nakamura M, Han B, Nunobiki O, Kakudo K (2006) Adrenomedullin: a tumor progression factor via angiogenic control. *Curr Cancer Drug Targets* 6:635–643
- Nothlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN (2007) Flavonols and pancreatic cancer risk: the multiethnic cohort study. *Am J Epidemiol* 166:924–931
- Ochi H, DeJesus NH, Hsieh FH, Austen KF, Boyce JA (2000) IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. *Proc Natl Acad Sci U S A* 97:10509–10513
- Parshad R, Kapoor S, Gupta SD, Kumar A, Chattopadhyaya TK (2002) Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. *Acta Oncol* 41:362–365
- Pedotti R, De Voss JJ, Steinman L, Galli SJ (2003) Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. *Trends Immunol* 24:479–484
- Polat A (2007) c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases. *Pathol Res Pract* 203:765–769
- Quan C, Wang HL, Lu SJ (2002) Resistance to mammary carcinogenesis in Copenhagen rats: potential roles of vascular endothelial growth factor and mast cells. *Cancer Lett* 186:165–175
- Rajput AB, Turbin DA, Cheang MCU, Voduc DK, Leung S et al (2007) Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. *Breast Cancer Res* 107:249–257
- Redegeld FA, Nijkamp FP (2003) Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? *Trends Immunol* 24:181–185
- Reed JA, McNutt NS, Bogdany JK, Albino AP (1996) Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. *J Cutan Pathol* 23:495–505
- Reubi JC, Waser B, Vale W, Rivier J (2003) Expression of CRF1 and CRF2 receptors in human cancers. *J Clin Endocrinol Metab* 88:3312–3320
- Reynolds JL, Akhter JA, Magarey CJ, Schwartz P, Adams WJ et al (1998) Histamine in human breast cancer. *Br J Surg* 85:538–541
- Ribatti D, Ennas MG, Vacca A, Ferrelì F, Nico B et al (2003) Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. *Eur J Clin Invest* 33:420–425
- Ribatti D, Finato N, Crivellato E, Guidolin D, Longo V et al (2007) Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases. *Histopathology* 51:837–842

- Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ (2009) Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. *Expert Opin Investig Drugs* 18:469–479
- Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T et al (2002) Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. *J Immunol* 169:469–475
- Salven P, Hattori K, Heissig B, Rafii S (2002) Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. *FASEB J* 16:1471–1473
- Samoszuk M, Corwin MA (2003) Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. *Int J Cancer* 107:159–163
- Schouten LJ, Rutten J, Huveneers HA, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. *Cancer* 94:2698–2705
- Shankar S, Ganapathy S, Hingorani SR, Srivastava RK (2008) EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. *Front Biosci* 13:440–452
- Sieghart W, Theoharides TC, Alper SL, Douglas WW, Greengard P (1978) Calcium-dependent protein phosphorylation during secretion by exocytosis in the mast cell. *Nature* 275:329–331
- Silzle T, Kreutz M, Dobler MA, Brockhoff G, Knuechel R et al (2003) Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. *Eur J Immunol* 33:1311–1320
- Sklar LS, Anisman H (1979) Stress and coping factors influence tumor growth. *Science* 205:513–515
- Sogno I, Vannini N, Lorusso G, Cammarota R, Noonan DM et al (2009) Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. *Recent Results Cancer Res* 181:209–212
- Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB et al (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. *Nat Med* 13:1211–1218
- Starkey JR, Crowle PK, Taubenberger S (1988) Mast-cell-deficient W/W<sup>v</sup> mice exhibit a decreased rate of tumor angiogenesis. *Int J Cancer* 42:48–52
- Sternlicht MD, Lochter A, Sympon CJ, Huey B, Rougier JP et al (1999) The stromal proteinase MMP3/Stromelysin-1 promotes mammary carcinogenesis. *Cell* 98:134–146
- Strum JM, Lewko WM, Kidwell WR (1981) Structural alterations within N-nitrosomethylurea-induced mammary tumors after in vivo treatment with cis-hydroxyproline. *Lab Invest* 45:347–354
- Su MY, Najafi A, Nalcioglu O (2001) Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. *Am J Pathol* 159:245–251
- Takada M, Nakamura Y, Koizumi T, Toyama H, Kamigaki T et al (2002) Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. *Pancreas* 25:45–48
- Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. *Cancer* 88:2686–2692
- Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D et al (2004) IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. *Blood* 103:3837–3844
- Theoharides TC (1988) Neuroimmunology of tumor growth: the role of mast cells. *Int J Immunopath Pharmacol* 1:89–98
- Theoharides TC (2008) Mast cells and pancreatic cancer. *N Engl J Med* 358:1860–1861
- Theoharides TC, Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* 146:1–12
- Theoharides TC, Douglas WW (1978) Secretion in mast cells induced by calcium entrapped within phospholipid vesicles. *Science* 201:1143–1145
- Theoharides TC, Kalogeromitros D (2006) The critical role of mast cell in allergy and inflammation. *Ann N Y Acad Sci* 1088:78–99

- Theoharides TC, Sieghart W, Greengard P, Douglas WW (1980) Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* 207:80–82
- Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW (1982) Differential release of serotonin and histamine from mast cells. *Nature* 297:229–231
- Theoharides TC, Sant GR, El-Mansoury M, Letourneau RJ, Ucci AA Jr et al (1995) Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. *J Urol* 153:629–636
- Theoharides TC, Patra P, Boucher W, Letourneau R, Kempuraj D et al (2000) Chondroitin sulfate inhibits connective tissue mast cells. *Br J Pharmacol* 131:1039–1049
- Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. *Immunol Rev* 217:65–78
- Theoharides TC, Rozniecki JJ, Sahagian G, Kempuraj D, Kalogeromitros D et al (2008) Impact of stress and mast cells on brain metastases. *J Neuroimmunol* 205:1–7
- Tiligada E, Zampeli E, Sander K, Stark H (2009) Histamine H3 and H4 receptors as novel drug targets. *Expert Opin Investig Drugs* 18:1519–1531
- Tomita M, Matsuzaki Y, Onitsuka T (2000) Effect of mast cells on tumor angiogenesis in lung cancer. *Ann Thorac Surg* 69:1686–1690
- Tuveson DA, Hingorani SR (2005) Ductal pancreatic cancer in humans and mice. *Cold Spring Harb Symp Quant Biol* 70:65–72
- Vliagoftis H, Boucher WS, Mak LL, Theoharides TC (1992) Inhibition of mast cell secretion by oxidation products of natural polyamines. *Biochem Pharmacol* 43:2237–2245
- Walls AF, Roberts JA, Godfrey RC, Holgate ST (2007) Histochemical heterogeneity of human mast cells: disease-related differences in mast cell subsets recovered by bronchoalveolar lavage. *Int Arch Allergy Appl Immunol* 92:233–241
- Wang SH, Mezosi E, Wolf JM, Cao Z, Utsugi S et al (2004) IFN $\gamma$  sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. *Oncogene* 23:928–935
- Wasiuk A, de V V, Hartmann K, Roers A, Noelle RJ (2009) Mast cells as regulators of adaptive immunity to tumours. *Clin Exp Immunol* 155:140–146
- Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. *Clin Cancer Res* 14:6735–6741
- Wedemeyer J, Galli SJ (2005) Decreased susceptibility of mast cell-deficient kit(W)Kit(W-v) mice to the development of 1,2-dimethylaziridine-induced intestinal tumors. *Lab Invest* 85:388–396
- Welker P, Schadendorf D, Artuc M, Grabbe J, Henz BM (2000) Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications. *Br J Cancer* 82:1453–1458
- Welsch T, Kleeff J, Friess H (2007) Molecular pathogenesis of pancreatic cancer: advances and challenges. *Curr Mol Med* 7:504–521
- Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B et al (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell* 6:409–421
- Yoshida M, Yoshida H, Kitaichi K, Hiramatsu K, Kimura T et al (2001) Adrenomedullin and proadrenomedullin N-terminal 20 peptide induce histamine release from rat peritoneal mast cells. *Regul Pept* 101:163–168
- Yu JL, Rak JW (2003) Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. *Breast Cancer Res* 5:83–88
- Zudaire E, Martinez A, Garayoa M, Pio R, Kaur G et al (2006) Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. *Am J Pathol* 168:280–291